Promega’s New Capillary Electrophoresis Instrument Enhances Benchtop Analysis
The new personal capillary electrophoresis system, Spectrum Compact CE, performs Sanger sequencing and fragment analysis.
A new benchtop capillary electrophoresis (CE) instrument, the Spectrum Compact CE System, an integrated DNA analysis instrument by Promega, a provider of innovative solutions and technical support to the life sciences industry, enhances analysis by enabling the ability to perform Sanger sequencing and fragment analysis at the bench. The system, which was developed in collaboration with Hitachi High-Tech, can be used by life scientists in laboratories of all sizes.
The Spectrum Compact CE System features:
- Flexible run scheduling
- An easy-to-use interface
- Convenient benchtop size
- Separate plug-and-play consumables
- On-site installation and operational training.
The instrument also supports applications such as microsatellite instability analysis, mixed sample analysis, forensic short tandem repeat analysis, and cell line authentication. The instrument can process up to 32 samples in a single run and can be controlled by either an integrated touchscreen or by additional software that allows access from any registered computer on the same network.
“The Spectrum Compact CE is personal, and that’s one of the huge advantages that scientists will see with this instrument,” said Promega Head of Research Doug Storts, in an Aug. 31, 2020 press release. “An individual can walk into the laboratory and, with minimal training, be able to change all the consumables, select which chemistries they want to use for both DNA sequencing as well as for fragment analysis, and perform the experiment. Literally everybody has access. It democratizes the use of the instrument in the laboratory.”
Promega also offers support to laboratories integrating a Spectrum Compact CE System into their workflow, including on-site instrument and software installation and operational training. Technical services scientists can assist with data analysis and summary reports, and field support and validation services scientists will be made available to assist with maintenance and validation requirements.
Promega launched the new system in August 2020.
Source: Promega
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
